Drugs / Ludotadipep
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05458544 | Sep 2022 → Jun 2025 | castration-resistant prostate carcinoma | FutureChem | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ludotadipep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05458544 ↗ |
| Route | Intravenous | “Administration route: intravenous injection” NCT05458544 ↗ |